MYWOT
Child safety
Confidence
Trustworthiness
Confidence
MALICIOUS CONTENT INDICATORS
Investor.jazzpharma.com most likely does not offer any malicious content.
Secure connection support
HTTPS
Investor.jazzpharma.com provides SSL-encrypted connection.
ADULT CONTENT INDICATORS
Investor.jazzpharma.com most likely does not offer any adult content.
Popular pages
-
Investors | Jazz Pharmaceuticals plc
The Investor Relations website contains information about Jazz Pharmaceuticals plc's business for stockholders, potential investors, and financial analysts.
-
Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2022 Financial Results and Provides 2023
Strong Execution Drove Record Revenues in 2022 of $3.7 billion , an increase of 18% over 2021 Positioned for Total Revenue and Net Income Growth in 2023 Xywav Enters 2023 as the Oxybate Therapy of C...
-
Quarterly Results | Jazz Pharmaceuticals plc
U.S.: +1 650 496 2717
-
Jazz Pharmaceuticals Announces First Quarter 2023 Financial Results and Affirms 2023 Financial
Focus on commercial execution drove 1Q23 total revenues of $892.8 million Continued adoption of Xywav ® ; net product sales increased 49% 1Q23 compared to 1Q22 Confident in blockbuster potential of Ep...
-
Jazz Pharmaceuticals Announces Second Quarter 2022 Financial Results and Affirms 2022 Financial
DUBLIN , Aug. 3, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the second quarter of 2022, affirmed 2022 financial guidance 1 and provided business...
-
JAZZ PHARMACEUTICALS ANNOUNCES FULL YEAR AND FOURTH QUARTER 2021 FINANCIAL RESULTS | Jazz
DUBLIN , March 1, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the full year and fourth quarter of 2021 and provided financial guidance for 2022. ...